Thomas Catinazzo Sells 20,791 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 20,791 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $4.42, for a total transaction of $91,896.22. Following the completion of the sale, the chief financial officer now directly owns 379,431 shares in the company, valued at approximately $1,677,085.02. The trade was a 5.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, January 28th, Thomas Catinazzo sold 36,036 shares of Relay Therapeutics stock. The stock was sold at an average price of $4.63, for a total transaction of $166,846.68.
• On Friday, December 27th, Thomas Catinazzo sold 4,865 shares of Relay Therapeutics stock. The shares were sold at an average price of $4.42, for a total transaction of $21,503.30.

Relay Therapeutics Stock Performance

Shares of Relay Therapeutics stock opened at $4.47 on Friday. Relay Therapeutics, Inc. has a 52-week low of $3.50 and a 52-week high of $11.16. The company has a fifty day moving average of $4.53 and a 200-day moving average of $6.11. The stock has a market capitalization of $748.19 million, a price-to-earnings ratio of -1.71 and a beta of 1.60.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.14. During the same quarter in the prior year, the company earned ($0.54) earnings per share. Relay Therapeutics’s revenue was down 100.0% compared to the same quarter last year. On average, equities research analysts forecast that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Leerink Partners lowered their price objective on Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 4th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Relay Therapeutics in a research report on Tuesday, January 14th. Finally, JMP Securities restated a “market outperform” rating and issued a $21.00 price objective on shares of Relay Therapeutics in a research report on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.50.

Institutional Investors Weigh In On Relay Therapeutics

Institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in Relay Therapeutics in the 3rd quarter worth approximately $63,000. Portland Investment Counsel Inc. purchased a new position in shares of Relay Therapeutics in the third quarter worth $71,000. Values First Advisors Inc. purchased a new stake in Relay Therapeutics during the 3rd quarter valued at $75,000. Point72 DIFC Ltd bought a new stake in Relay Therapeutics in the 3rd quarter worth $134,000. Finally, Erste Asset Management GmbH purchased a new position in shares of Relay Therapeutics in the third quarter valued at about $172,000. 96.98% of the stock is currently owned by hedge funds and other institutional investors.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.